332 related articles for article (PubMed ID: 23075026)
1. Demystifying brain penetration in central nervous system drug discovery. Miniperspective.
Di L; Rong H; Feng B
J Med Chem; 2013 Jan; 56(1):2-12. PubMed ID: 23075026
[TBL] [Abstract][Full Text] [Related]
2. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.
Zhuang Y; Fraga CH; Hubbard KE; Hagedorn N; Panetta JC; Waters CM; Stewart CF
Cancer Res; 2006 Dec; 66(23):11305-13. PubMed ID: 17145877
[TBL] [Abstract][Full Text] [Related]
3. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
[TBL] [Abstract][Full Text] [Related]
4. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
5. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
[TBL] [Abstract][Full Text] [Related]
6. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
[TBL] [Abstract][Full Text] [Related]
7. Progress in brain penetration evaluation in drug discovery and development.
Liu X; Chen C; Smith BJ
J Pharmacol Exp Ther; 2008 May; 325(2):349-56. PubMed ID: 18203948
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers.
Miller DW; Hinton M; Chen F
Neurourol Urodyn; 2011 Nov; 30(8):1633-8. PubMed ID: 21826715
[TBL] [Abstract][Full Text] [Related]
9. Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2).
Nicolazzo JA; Katneni K
Curr Top Med Chem; 2009; 9(2):130-47. PubMed ID: 19200001
[TBL] [Abstract][Full Text] [Related]
10. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
Nagasaka Y; Oda K; Iwatsubo T; Kawamura A; Usui T
Biopharm Drug Dispos; 2012 Sep; 33(6):304-15. PubMed ID: 22847220
[TBL] [Abstract][Full Text] [Related]
11. A Practical Perspective on the Evaluation of Small Molecule CNS Penetration in Drug Discovery.
Huang L; Wells MC; Zhao Z
Drug Metab Lett; 2019; 13(2):78-94. PubMed ID: 30854983
[TBL] [Abstract][Full Text] [Related]
12. High brain distribution of a new central nervous system drug candidate despite its P-glycoprotein-mediated efflux at the mouse blood-brain barrier.
Taccola C; Cartot-Cotton S; Valente D; Barneoud P; Aubert C; Boutet V; Gallen F; Lochus M; Nicolic S; Dodacki A; Smirnova M; Cisternino S; Declèves X; Bourasset F
Eur J Pharm Sci; 2018 May; 117():68-79. PubMed ID: 29427702
[TBL] [Abstract][Full Text] [Related]
13. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development.
Ohtsuki S; Terasaki T
Pharm Res; 2007 Sep; 24(9):1745-58. PubMed ID: 17619998
[TBL] [Abstract][Full Text] [Related]
14. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
[TBL] [Abstract][Full Text] [Related]
15. Prediction of brain:blood unbound concentration ratios in CNS drug discovery employing in silico and in vitro model systems.
Liu H; Dong K; Zhang W; Summerfield SG; Terstappen GC
Drug Discov Today; 2018 Jul; 23(7):1357-1372. PubMed ID: 29548981
[TBL] [Abstract][Full Text] [Related]
16. Regulation of ABC transporters blood-brain barrier: the good, the bad, and the ugly.
Miller DS
Adv Cancer Res; 2015; 125():43-70. PubMed ID: 25640266
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a new conditionally immortalized cell line from human brain microvascular endothelial cells: a promising tool for human blood-brain barrier studies.
Kamiichi A; Furihata T; Kishida S; Ohta Y; Saito K; Kawamatsu S; Chiba K
Brain Res; 2012 Dec; 1488():113-22. PubMed ID: 23041702
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
[TBL] [Abstract][Full Text] [Related]
20. Role of breast cancer resistance protein (BCRP) as active efflux transporter on blood-brain barrier (BBB) permeability.
Garg P; Dhakne R; Belekar V
Mol Divers; 2015 Feb; 19(1):163-72. PubMed ID: 25502234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
